{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,7,11]],"date-time":"2025-07-11T10:55:32Z","timestamp":1752231332212},"reference-count":17,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2015,1]]},"DOI":"10.1097\/nrl.0b013e318287fde0","type":"journal-article","created":{"date-parts":[[2015,1,20]],"date-time":"2015-01-20T17:59:14Z","timestamp":1421776754000},"page":"35-37","source":"Crossref","is-referenced-by-count":8,"title":["Cytomegalovirus Meningoencephalitis After Rituximab Treatment for Primary Central Nervous System Lymphoma"],"prefix":"10.1097","volume":"19","author":[{"given":"Marina P.","family":"Siakantaris","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kimon V.","family":"Argyropoulos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Savvas","family":"Ioannou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vasiliki","family":"Papadopoulou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"George","family":"Tzeletas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John","family":"Tsonis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aglaia","family":"Dimitrakopoulou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Konstantina G.","family":"Yiannopoulou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gerassimos A.","family":"Pangalis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"George","family":"Vaiopoulos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"R1-1-20210211","first-page":"143","article-title":"Primary lymphoma of the central nervous system: epidemiology, pathology and current approaches to diagnosis, prognosis and treatment.","volume":"49S","author":"Rubenstein","year":"2008","journal-title":"Leuk Lymphoma"},{"key":"R2-1-20210211","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1080\/08820530500350498","article-title":"Primary intraocular lymphoma: a review.","volume":"21","author":"Choi","year":"2006","journal-title":"Semin Ophthalmol"},{"key":"R3-1-20210211","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1111\/j.1365-2141.2010.08321.x","article-title":". Treatment of isolated primary intraocular lymphoma with high-dose methotrexate-based chemotherapy and binocular radiation therapy: a single-institution experience.","volume":"151","author":"Stefanovic","year":"2010","journal-title":"Br J Haematol"},{"key":"R5-1-20210211","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1002\/cncr.10643","article-title":"Decreasing incidence rates of primary central nervous system lymphoma.","volume":"95","author":"Kadan-Lottick","year":"2002","journal-title":"Cancer"},{"key":"R6-1-20210211","first-page":"247","article-title":". Diagnosis and management of primary intraocular lymphoma: an update.","volume":"1","author":"Jahnke","year":"2007","journal-title":"Clin Ophthalmol"},{"key":"R7-1-20210211","doi-asserted-by":"crossref","first-page":"1512","DOI":"10.1016\/S0140-6736(09)61416-1","article-title":". High-dose cytarabine plus high-dose methotrexate versus high-dose methotrexate alone in patients with primary CNS lymphoma: a randomised phase 2 trial.","volume":"374","author":"Ferreri","year":"2009","journal-title":"Lancet"},{"key":"R8-1-20210211","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1007\/s00401-005-0023-y","article-title":"Cancer therapy-associated CNS neuropathology: an update and review of the literature.","volume":"111","author":"Perry","year":"2006","journal-title":"Acta Neuropathol"},{"key":"R9-1-20210211","doi-asserted-by":"crossref","first-page":"1000","DOI":"10.1056\/NEJM200109273451315","article-title":"Fatal reactivation of cytomegalovirus infection after use of rituximab for a posttransplantation lymphoproliferative disorder.","volume":"345","author":"Suzan","year":"2001","journal-title":"N Engl J Med"},{"key":"R10-1-20210211","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1007\/s00277-007-0397-0","article-title":". Rituximab therapy increased post-transplant cytomegalovirus complications in Non-Hodgkins lymphoma patients receiving autologous hematopoietic stem cell transplantation.","volume":"87","author":"Lee","year":"2008","journal-title":"Ann Hematol"},{"key":"R11-1-20210211","doi-asserted-by":"crossref","first-page":"1307","DOI":"10.1080\/10428190701411441","article-title":". Rituximab-related viral infections in lymphoma patients.","volume":"48","author":"Aksoy","year":"2007","journal-title":"Leuk Lymphoma"},{"key":"R12-1-20210211","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1002\/ajh.21484","article-title":". Fatal CMV pneumonitis in a lymphoma patient treated with rituximab.","volume":"84","author":"Sharma","year":"2009","journal-title":"Am J Hematol"},{"key":"R13-1-20210211","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1634\/theoncologist.2008-0236","article-title":". Primary CNS lymphoma in immunocompetent patients.","volume":"14","author":"Sierra del Rio","year":"2009","journal-title":"Oncologist"},{"key":"R14-1-20210211","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1053\/j.seminhematol.2010.01.002","article-title":"Rituximab-associated infections.","volume":"47","author":"Gea-Banacloche","year":"2010","journal-title":"Semin Hematol"},{"key":"R15-1-20210211","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1634\/theoncologist.2010-0106","article-title":". Hepatitis B reactivation and rituximab in the oncology practice.","volume":"15","author":"Villadolid","year":"2010","journal-title":"Oncologist"},{"key":"R16-1-20210211","doi-asserted-by":"crossref","first-page":"1214","DOI":"10.1634\/theoncologist.2010-0098","article-title":". Inclusion of rituximab in treatment protocols for non-Hodgkins lymphomas and risk for progressive multifocal leukoencephalopathy.","volume":"15","author":"Tuccori","year":"2010","journal-title":"Oncologist"},{"key":"R17-1-20210211","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1111\/j.1365-2141.2010.08076.x","article-title":"The effect of rituximab on humoral and cell mediated immunity and infection in the treatment of autoimmune diseases.","volume":"149","author":"Cooper","year":"2010","journal-title":"Br J Haematol"},{"key":"R18-1-20210211","first-page":"35","article-title":"A, Cinque P, Vago L, Rocca A, et al.. A comparison of brain biopsy and CSF-PCR in the diagnosis of CNS lesions in AIDS patients.","volume":"244","year":"1997","journal-title":"J Neurol"}],"container-title":["The Neurologist"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/NRL.0b013e318287fde0","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,14]],"date-time":"2021-05-14T04:41:30Z","timestamp":1620967290000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00127893-201501000-00001"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,1]]},"references-count":17,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2015]]}},"URL":"https:\/\/doi.org\/10.1097\/nrl.0b013e318287fde0","relation":{},"ISSN":["1074-7931"],"issn-type":[{"value":"1074-7931","type":"print"}],"subject":[],"published":{"date-parts":[[2015,1]]}}}